Integrin αvβ6-targeted PET in Malignant Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorZhongnan Hospital
About this trial
Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.
Eligibility criteria
Qualifiers
Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
Age ≥18 years, regardless of gender;
No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
Disqualifiers
Known allergy to injection or its excipients;
Severe liver or renal dysfunction;
Claustrophobia or other psychiatric disorders;
History of other malignant tumors;
Trial design
Treatments tested in this trial
- PET/CT scans
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov